Form 4: Allogene CTO Sells Shares for Tax, Receives New Equity Grants

Allogene Therapeutics' SVP, Chief Technical Officer, Benjamin Beneski, sold shares to cover tax obligations and was granted new stock options and restricted stock units.

Summary

• Benjamin Beneski, SVP, Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO), disposed of 7,549 shares of common stock on February 2, 2026, at a weighted average price of $1.73 per share.
• The sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plan to satisfy tax withholding obligations related to the vesting of restricted stock units, and was not a discretionary trade.
• Following the sale, Beneski beneficially owns 210,172 shares of common stock directly.
• Beneski was granted 373,757 stock options on February 2, 2026, with an exercise price of $1.87 per share.
• These stock options will vest 25% on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, and expire on February 2, 2036.
• Additionally, Beneski was awarded 105,720 Restricted Stock Units (RSUs) on February 2, 2026.
• The RSUs will vest in 4 successive equal annual installments over a four-year period from February 2, 2026, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a share sale, it's non-discretionary for tax purposes, and the significant new equity grants demonstrate continued executive incentive and commitment to the company's long-term performance.

Positives

• The grant of 373,757 stock options and 105,720 Restricted Stock Units (RSUs) indicates continued incentive and alignment of management interests with shareholder value over the long term.
• The vesting schedules for both the stock options (over 3 years after initial 25%) and RSUs (over 4 years) promote long-term retention and performance.

Negatives

• The sale of 7,549 shares, even for tax purposes, represents a reduction in direct common stock ownership by a key executive.

Future Outlook

The filing details future vesting schedules for newly granted stock options and restricted stock units, indicating a long-term incentive structure for the SVP, Chief Technical Officer, contingent on continued service through the vesting dates.

Industry Context

StockSavvy.ai notes that equity grants and 'sell to cover' transactions are standard practices in the biotechnology industry for executive compensation and tax management. These actions reflect routine compensation structures designed to align executive incentives with long-term company performance and shareholder value, common across publicly traded biotech firms like Allogene Therapeutics.

Comparison to Industry Standards

• The 'sell to cover' transaction for tax withholding is a common mechanism in equity compensation plans across industries, including biotechnology, to manage tax liabilities upon RSU vesting.
• The grant of stock options and RSUs with multi-year vesting schedules is consistent with typical executive compensation packages in the biotech sector, aiming to retain talent and incentivize long-term performance, similar to practices at companies like Gilead Sciences or Amgen.

Stakeholder Impact

• Shareholders: The 'sell to cover' transaction has a minimal dilutive effect, while the new equity grants align executive incentives with long-term shareholder value.
• Employees (specifically the CTO): The grants provide significant long-term compensation and retention incentives, contingent on continued service.

Next Steps

• The granted stock options will begin vesting on February 2, 2027, with subsequent monthly installments.
• The Restricted Stock Units will vest in four successive equal annual installments starting from February 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically a 'sell to cover' for tax obligations and new equity grants. These are standard compensation events and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. The grants indicate continued executive alignment, but the overall impact on the stock's valuation is neutral, suggesting a 'hold' position for existing investors.

Keywords

Allogene Therapeutics, ALLO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation, Sell to Cover, Biotechnology